Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States



Survival: 10.0 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Pittsburgh, Pennsylvania
   
Hospital: University of Pittsburgh Cancer Institute
   
Journal: Link
   
Date: 2/2010

Description:
Patients:
This phase II study involved 251 patients with relapsed or refractory melanoma. The median age was 53 years and 60% were male.

Treatment:
Patients were treated with the biologic therapy agent tremelimumab, which is a monoclonal antibody that binds to a protein called CTLA-4 and helps the immune system attack tumor cells.

Toxicities:
There were two treatment-related deaths due to sudden death and diverticular perforation. Grade 3/4 diarrhea, fatigue, and colitis were also reported.

Results:
The median overall survival was 10.0 months.

Support:
This study was supported by the pharmaceutical company Pfizer, makers of Tremelimumab.

Correspondence: Dr. John M. Kirkwood; email: kirkwoodjm@upmc.edu

E-mail to a Friend Email Physician More Information